Azelta 75 mg 10 tablets — Made in Poland — Free Delivery

Azelt tablets are indicated for the treatment and prevention of influenza.

Active substance: oseltamivir;

1 tablet contains oseltamivir 75.00 mg in the form of oseltamivir phosphate 98.50 mg;

Excipients: microcrystalline cellulose (type 102), crospovidone, microcrystalline cellulose (type 101), colloidal silicon dioxide, povidone, magnesium stearate.

Hypersensitivity to the active substance or other components of the preparation.

Moderate or severe renal impairment.

Body weight less than 40 kg.

Orally.

Swallow the tablets whole with water.

Pregnant

If necessary, the use of oseltamivir during pregnancy may be considered in the light of the available safety and benefit information and the pathogenicity of the circulating influenza virus strain.

Children

The preparation Azelta should be used in children aged 6 years and older with a body weight of more than 40 kg.

Drivers

Oseltamivir does not affect the reaction rate when driving or using other mechanisms.

Oseltamivir overdose has been reported during clinical trials and during post-marketing use of the preparation. In most of the recorded cases of overdose, no adverse reactions were reported. The adverse reactions reported in overdose were similar in nature and type to those observed with therapeutic doses of oseltamivir.

There is no specific antidote.

Infections and invasions: often - bronchitis, herpes simplex, upper respiratory tract infections, nasopharyngitis, sinusitis.

On the part of the blood and lymphatic system: rarely - thrombocytopenia.

From the immune system: rarely - hypersensitivity reaction; rarely - anaphylactic and anaphylactoid reactions.

Mental disorders: rarely - agitation, pathological behavior, anxiety, confusion, delirium, delirium, hallucinations, nightmares, self-trauma.

From the side of the nervous system: very often - headache; often - insomnia; sometimes - impaired consciousness, convulsions.

From the side of the organs of vision: rarely - visual impairment.

From the side of the cardiovascular system: sometimes - cardiac arrhythmias.

From the respiratory system, chest and mediastinal organs: often - cough, rhinorrhea, sore throat.

From the gastrointestinal tract: very often - nausea; often - vomiting, abdominal pain (including in the upper sections), dyspepsia, rarely - gastrointestinal bleeding, hemorrhagic colitis.

On the part of the digestive system: rarely - an increase in the level of liver enzymes; rarely - fulminant hepatitis, liver failure, hepatitis.

On the part of the skin and subcutaneous tissue: sometimes - dermatitis, rashes, eczema, urticaria, rarely - angioedema, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, the frequency is unknown - allergies, facial edema.

General disorders and reactions at the injection site: often - dizziness (including vertigo), weakness, pain, pyrexia, pain in the extremities.

With the simultaneous administration of oseltamivir and probenecid for patients with normal renal function, dose adjustment is not required. Concomitant use of probenecid, which is a potent inhibitor of the anionic pathway of renal tubular secretion, approximately doubles the exposure to the active metabolite of oseltamivir.

Store at a temperature not exceeding 25 ° C. Keep out of the reach of children.

Shelf life is 3 years.